Business Insider19d
Viking Therapeutics’ VK2735: A Promising Contender in the Weight-Loss Market with Superior Efficacy Profile
Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may demonstrate superior weight loss outcomes compared to semaglutide ... s CagriSema trials present an opportunity for Viking ...
Business Insider27d
Viking Therapeutics’ oral-2735 could differentiate asset, says JPMorgan
JPMorgan keeps an Overweight rating and $80 price target on Viking Therapeutics (VKTX) after the company announced that it has initiated the ph2a trial for oral 2735, a dual GIP/GLP-1 dual agonist.
Nasdaq28d
Viking Therapeutics initiates Phase 2 VENTURE-oral dosing trial of VK2735
Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose ...
Investing15d
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data
Novo Nordisk reported that adults with obesity achieved significant weight loss using their semaglutide ... CagriSema. The maintained Buy rating and price target reflect a positive outlook for ...